Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 9Ovarian Neoplasms 8Uterine Cervical Neoplasms 6Pancreatic Neoplasms 4Brenner Tumor 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Thymoma 2Testicular Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Oropharyngeal Neoplasms 2Neurotoxicity Syndromes 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2HIV Infections 2Esophageal Neoplasms 2Endometrial Clear Cell Adenocarcinoma 2Endometrial Adenocarcinoma 2Carcinoma, Ovarian Epithelial 2Anus Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Urinary Bladder Neoplasms 1Teratoma, Testicular 1Teratoma, Ovarian 1Teratoma 1Sertoli-Leydig Cell Tumor 1

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Carcinoma × Taxes × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡